Jagsonpal Pharmaceuticals Board Meeting on Oct 28 to Approve Q2 Results
Jagsonpal Pharmaceuticals Ltd has announced that its Board of Directors will convene on October 28, 2026. The primary agenda item is the consideration and approval of the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2026. Additionally, the company confirmed that the trading window for its securities will remain closed until October 30, 2026, following its earlier intimation on September 25, 2026.
Key Highlights
- Board meeting scheduled for October 28, 2026.
- Agenda includes approval of Q2 Unaudited Financial Results.
- Trading window closure extended until October 30, 2026.
- Compliance with SEBI Listing Regulations confirmed.
Price Impact
More from JAGSNPHARM
Jagsonpal Pharmaceuticals Consummates Group Pharma Wellness Portfolio Acquisition
Jagsonpal Pharma: Trading Window Closed for Q2 FY27 Results
Jagsonpal Pharma Acquires Group Pharma Wellness Portfolio for ₹46.7 Cr
More in Board Meeting
Popees Baby Care Board Meeting Oct 24 for Fund Raising Modification
Virtual Global Education Board Approves Financial Results, CFO Change, and Fund Raise
Virtual Global Education Board Approves Financial Results, CFO Change, and Fund Raise